BeOne Medicines Ltd
128 hedge funds and large institutions have $6.49B invested in BeOne Medicines Ltd in 2018 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 43 increasing their positions, 44 reducing their positions, and 23 closing their positions.
22% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 23
6% more capital invested
Capital invested by funds: $6.12B → $6.49B (+$366M)
4% more funds holding
Funds holding: 123 → 128 (+5)
0.81% more ownership
Funds ownership: 5.23% → 6.04% (+0.81%)
2% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 44
18% less funds holding in top 10
Funds holding in top 10: 11 → 9 (-2)
26% less call options, than puts
Call options by funds: $17.7M | Put options by funds: $23.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$1.09B |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$230M |
| 3 |
Renaissance Technologies
New York
|
+$38.7M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$28.3M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$27.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$184M |
| 2 |
Janus Henderson Group
London,
|
-$99.6M |
| 3 |
ICP
Indus Capital Partners
New York
|
-$49.5M |
| 4 |
PSCM
Prince Street Capital Management
New York
|
-$45.5M |
| 5 |
Goldman Sachs
New York
|
-$31.2M |
ONC Hedge Fund Activity: Q2 2018 in Review
128 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines Ltd (ONC) for Q2 2018, worth a combined $6.49B — up 6% from $6.12B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new ONC positions and 23 closed out — a net gain of 5 holders — while 43 added to existing stakes and 44 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $1.09B. The largest seller was Wellington Management Group, cutting an estimated $184M.
- 128 institutional investors held BeOne Medicines Ltd (ONC) as of Q2 2018, up from 123 in Q1 2018.
- Funds reported $6.49B of BeOne Medicines Ltd stock for Q2 2018, up 6% quarter-over-quarter.
- 28 funds opened new BeOne Medicines Ltd positions in Q2 2018 and 23 closed out, a net change of +5 holders.
- The largest BeOne Medicines Ltd buyer in Q2 2018 was Baker Bros. Advisors, an estimated $1.09B added.
- The largest BeOne Medicines Ltd seller in Q2 2018 was Wellington Management Group, an estimated $184M sold.
Based on aggregated 13F filings for Q2 2018.